EGFR and non-small cell lung carcinoma: However, our statistical results demonstrated that there was a remarkable difference in response to TKIs in NSCLC patients containing EGFR mutant with or without BIM deletion polymorphism (p < 0.05), indicating that BIM polymorphism was closely related to curative effect of NSCLC patients.